Page last updated: 2024-11-13

anagliptin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

anagliptin: anagliptin hydrochloride salt is the active compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44513473
CHEMBL ID1929396
CHEMBL ID1929387
CHEBI ID136043
SCHEMBL ID905393
MeSH IDM0587395

Synonyms (38)

Synonym
anagliptin
CHEBI:136043
739366-20-2
D09780
anagliptin (jan/inn)
anagliptin [inn]
pyrazolo(1,5-a)pyrimidine-6-carboxamide, n-(2-((2-((2s)-2-cyano-1-pyrrolidinyl)-2-oxoethyl)amino)-2-methylpropyl)-2-methyl-
k726j96838 ,
unii-k726j96838
sk-0403
suiny
CHEMBL1929396 ,
cwp-403
bdbm50359366
CHEMBL1929387 ,
anagliptin [mi]
anagliptin [jan]
anagliptin [who-dd]
n-(2-((2-((2s)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo(1,5-a)pyrimidine-6-carboxamide
S5909
CS-4510
SCHEMBL905393
n-[2-({2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
n-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
HY-14877
AKOS027325601
LDXYBEHACFJIEL-HNNXBMFYSA-N
(s)-n-(2-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide ,
NCGC00484798-01
DB12417
Q15269682
mfcd19443729
gtpl11582
compound 4a [pmid: 22019046]
sk0403
A916481
MS-26302
DTXSID401045689

Research Excerpts

Overview

Anagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of hyperglycemia.

ExcerptReferenceRelevance
"Anagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of hyperglycemia."( Anagliptin prevented interleukin 1β (IL-1β)-induced cellular senescence in vascular smooth muscle cells through increasing the expression of sirtuin1 (SIRT1).
He, X; Li, X; Sun, Z; Zhao, J; Zuo, M, 2021
)
2.79
"Anagliptin is a novel licensed dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of T2DM."( Anagliptin ameliorates high glucose- induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1.
Ding, M; Jiang, D; Jiang, T; Zhang, L; Zhou, H, 2019
)
2.68

Actions

Anagliptin promotes insulin production via inhibition of dipeptidyl peptidase IV (DPP-4) DPP-4 is an enzyme that targets the incretin hormone glucagon-like peptide 1 (GLP-1) for degradation. AnAGliptin caused an increase in the serum active GLP‑1 concentration, compared with the injury group.

ExcerptReferenceRelevance
"Anagliptin promotes insulin production via inhibition of dipeptidyl peptidase IV (DPP-4), an enzyme that targets the incretin hormone glucagon-like peptide 1 (GLP-1) for degradation."( Anagliptin stimulates osteoblastic cell differentiation and mineralization.
Cao, Z; Dong, C; Li, D; Ning, Y; Wang, Y; Yan, X; Yang, H; Zhang, C, 2020
)
2.72
"Anagliptin caused an increase in the serum active GLP‑1 concentration, compared with the injury group."( The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury.
Bai, X; Chen, C; Li, Q; Liu, Y; Wu, X; Zhang, M, 2017
)
1.54

Treatment

Anagliptin treatment significantly decreased the plasma total cholesterol (14% reduction, P < 0.01) and triglyceride levels (27% reduction), compared with the injury group. Treatment ameliorated the impaired insulin-induced increase in capillary blood volume, interstitial insulin concentration and skeletal muscle glucose uptake in ETIrs2KO mice. Anagli leptin treatment effectively prevented inflammation, fibrosis, and carcinogenesis in the liver of MC4R- KO mice.

ExcerptReferenceRelevance
"Anagliptin treatment effectively prevented inflammation, fibrosis, and carcinogenesis in the liver of MC4R-KO mice."( Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Arima, H; Fujishiro, M; Goto, M; Ishigami, M; Ito, A; Itoh, M; Kanai, S; Kanamori, Y; Kawakubo, M; Ochi, K; Ogawa, Y; Saka-Tanaka, M; Sawada, M; Shirakawa, I; Suganami, T; Suzuki, H; Tanaka, M; Watanabe, A; Yamashita, S; Yoshioka, N, 2020
)
1.28
"Anagliptin treatment attenuated the intima-media area and the intimal area by 43%."( Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Goto, M; Hashimoto, H; Hirano, T; Mori, Y; Takahashi, M; Yamashita, S, 2016
)
2.6
"Anagliptin treatment significantly decreased the plasma total cholesterol (14% reduction, P < 0.01) and triglyceride levels (27% reduction, P < 0.01). "( Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
Goto, M; Hagita, S; Inoue, K; Inoue, N; Ito, S; Itou, T; Kaku, K; Nakagawa, T; Tanabe, S; Yano, W; Yasumura, M; Yoshinaka, Y, 2017
)
2.13
"Treatment with anagliptin decreased balloon injury‑induced neointima formation, compared with the injury group (P<0.01)."( The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury.
Bai, X; Chen, C; Li, Q; Liu, Y; Wu, X; Zhang, M, 2017
)
1.16
"Treatment with anagliptin clearly improved body weight loss and disease activity index in the recovery phase."( Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis.
Ando, T; Funasaka, K; Goto, H; Hirayama, Y; Ishiguro, K; Maeda, K; Maeda, O; Matsushita, M; Mimura, S; Miyahara, R; Morise, K; Nakamura, M; Ozaki, N; Ujihara, M; Watanabe, O, 2013
)
1.01
"Treatment with anagliptin ameliorated the impaired insulin-induced increase in capillary blood volume, interstitial insulin concentration and skeletal muscle glucose uptake in ETIrs2KO mice. "( Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.
Goto, M; Iwayama, K; Jomori, T; Kadowaki, T; Kubota, N; Kubota, T; Moroi, M; Nakaya, K; Sato, H; Sugi, K; Takamoto, I; Tokuyama, K, 2016
)
2.23

Toxicity

ExcerptReferenceRelevance
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" The incidences of adverse or serious adverse events were similar among the three study groups."( A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Ahn, YB; Baik, SH; Cha, BS; Choi, SH; Chung, CH; Kim, DM; Kim, IJ; Kim, J; Lee, IK; Lee, MK; Min, KW; Park, IeB; Park, JH; Park, KS; Park, SW; Park, TS; Song, KH; Sung, YA; Yang, HK; Yoo, SJ; Yoon, KH, 2015
)
0.63

Pharmacokinetics

The pharmacokinetic disposition of anagliptin, an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated in male rats and dogs.

ExcerptReferenceRelevance
"The pharmacokinetic disposition of anagliptin, an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated in male rats and dogs."( Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.
Furuta, S; Furuta, Y; Hirooka, H; Miyoshi, M; Mizuno, Y; Tamura, M, 2013
)
0.95
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" Anagliptin was well absorbed in dogs (70."( Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.
Furuta, S; Furuta, Y; Hirooka, H; Miyoshi, M; Mizuno, Y; Tamura, M, 2013
)
1.59
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Therefore, Ana dosing might be useful to prevent ischemia-induced bladder dysfunctions."( Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation.
Hamakawa, T; Hotta, Y; Kataoka, T; Kawata, R; Kimura, K; Maeda, K; Naiki-Ito, A; Ohta, Y; Takahashi, S; Tokoro, M; Yasui, T, 2020
)
2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)72.70000.00070.97749.7000AID635580
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)0.00330.00010.444410.0000AID1897141
Prolyl endopeptidase FAPHomo sapiens (human)IC50 (µMol)72.70000.01201.15895.8300AID635580
Dipeptidyl peptidase 2Homo sapiens (human)IC50 (µMol)176.70000.00020.93166.6000AID635579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
angiogenesisProlyl endopeptidase FAPHomo sapiens (human)
proteolysisProlyl endopeptidase FAPHomo sapiens (human)
cell adhesionProlyl endopeptidase FAPHomo sapiens (human)
regulation of collagen catabolic processProlyl endopeptidase FAPHomo sapiens (human)
negative regulation of extracellular matrix disassemblyProlyl endopeptidase FAPHomo sapiens (human)
endothelial cell migrationProlyl endopeptidase FAPHomo sapiens (human)
proteolysis involved in protein catabolic processProlyl endopeptidase FAPHomo sapiens (human)
regulation of cell cycleProlyl endopeptidase FAPHomo sapiens (human)
regulation of fibrinolysisProlyl endopeptidase FAPHomo sapiens (human)
negative regulation of cell proliferation involved in contact inhibitionProlyl endopeptidase FAPHomo sapiens (human)
melanocyte proliferationProlyl endopeptidase FAPHomo sapiens (human)
positive regulation of execution phase of apoptosisProlyl endopeptidase FAPHomo sapiens (human)
melanocyte apoptotic processProlyl endopeptidase FAPHomo sapiens (human)
negative regulation of extracellular matrix organizationProlyl endopeptidase FAPHomo sapiens (human)
proteolysisDipeptidyl peptidase 2Homo sapiens (human)
lysosomal protein catabolic processDipeptidyl peptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingProlyl endopeptidase FAPHomo sapiens (human)
endopeptidase activityProlyl endopeptidase FAPHomo sapiens (human)
serine-type endopeptidase activityProlyl endopeptidase FAPHomo sapiens (human)
integrin bindingProlyl endopeptidase FAPHomo sapiens (human)
protein bindingProlyl endopeptidase FAPHomo sapiens (human)
peptidase activityProlyl endopeptidase FAPHomo sapiens (human)
serine-type peptidase activityProlyl endopeptidase FAPHomo sapiens (human)
dipeptidyl-peptidase activityProlyl endopeptidase FAPHomo sapiens (human)
identical protein bindingProlyl endopeptidase FAPHomo sapiens (human)
protein homodimerization activityProlyl endopeptidase FAPHomo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 2Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 2Homo sapiens (human)
serine-type exopeptidase activityDipeptidyl peptidase 2Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
extracellular spaceProlyl endopeptidase FAPHomo sapiens (human)
cytoplasmProlyl endopeptidase FAPHomo sapiens (human)
plasma membraneProlyl endopeptidase FAPHomo sapiens (human)
focal adhesionProlyl endopeptidase FAPHomo sapiens (human)
cell surfaceProlyl endopeptidase FAPHomo sapiens (human)
membraneProlyl endopeptidase FAPHomo sapiens (human)
lamellipodiumProlyl endopeptidase FAPHomo sapiens (human)
lamellipodium membraneProlyl endopeptidase FAPHomo sapiens (human)
ruffle membraneProlyl endopeptidase FAPHomo sapiens (human)
apical part of cellProlyl endopeptidase FAPHomo sapiens (human)
basal part of cellProlyl endopeptidase FAPHomo sapiens (human)
peptidase complexProlyl endopeptidase FAPHomo sapiens (human)
plasma membraneProlyl endopeptidase FAPHomo sapiens (human)
extracellular regionDipeptidyl peptidase 2Homo sapiens (human)
Golgi apparatusDipeptidyl peptidase 2Homo sapiens (human)
azurophil granule lumenDipeptidyl peptidase 2Homo sapiens (human)
intracellular membrane-bounded organelleDipeptidyl peptidase 2Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 2Homo sapiens (human)
vesicleDipeptidyl peptidase 2Homo sapiens (human)
vesicleDipeptidyl peptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID635579Inhibition of DPP-2 expressed in human Caco-2 cells using H-Lys-Ala-AMC as substrate preincubated for 30 mins before substrate addition measured after 20 mins by fluorescence assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhib
AID1395907Elimination half life in human2018European journal of medicinal chemistry, May-10, Volume: 151Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
AID1897141Inhibition of human DPP4 expressed in Silkworm baculovirus system preincubated for 30 mins followed by substrate addition and measured after 20 mins using Gly-Pro-4-methylcoumarin-7-amide as substrate by fluorescence assay2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.
AID635580Inhibition of human recombinant FAP expressed in baculovirus-infected Sf9 insect cells using H-Ala-Pro-AFC as substrate after 60 mins by fluorescence assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhib
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (70)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's50 (71.43)24.3611
2020's20 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.83 (24.57)
Research Supply Index4.47 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (22.86%)5.53%
Reviews5 (7.14%)6.00%
Case Studies4 (5.71%)4.05%
Observational0 (0.00%)0.25%
Other45 (64.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Non-interventional, Single Group, Open-label, Multicenter Observational Study to Evaluate the Efficacy and Safety of Anagliptin in Type 2 Diabetic Patients With Other DPP4is as Mono or Combination Therapy With Insufficient Glucose Control [NCT04267601]2,448 participants (Actual)Observational2017-07-06Active, not recruiting
A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients [NCT01529528]Phase 3117 participants (Actual)Interventional2011-05-31Completed
A Multicenter, Randomized, Double-blind, Double Dummy, Active-controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate the Efficacy and Safety of CWP-0403 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DM Insuf [NCT01529541]Phase 3200 participants (Anticipated)Interventional2011-05-31Completed
A Multi-center, Active Controlled, Randomized, Double-blinded, Parallel, Phase IV Study to Evaluate the Effect of Improving Glycemic Variability of Anagliptin Compared With Sitagliptin in Patients With Type 2 Diabetes Mellitus [NCT04810507]Phase 489 participants (Actual)Interventional2018-11-09Completed
Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial [NCT02330406]Phase 4353 participants (Actual)Interventional2015-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]